Roderick T. Bunch

<i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates

Changyu Wang, Kent Thudium, Minhua Han et al. · Cancer Immunology Research · 2014 · 585 citations

Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor.

Roderick T. Bunch, Alan Eastman · PubMed · 1996 · 221 citations

Cell Death, Cell Cycle, Cancer Biology +17

Interspecies Differences in Renal Localization of Cyclooxygenase Isoforms: Implications in Nonsteroidal Antiinflammatory Drug-Related Nephrotoxicity

Kanwar Nasir M. Khan, Catherine M. Venturini, Roderick T. Bunch et al. · Toxicologic Pathology · 1998 · 202 citations

Renal Pathology, Renal Inflammation, Pathology +19

The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells.

Catherine Demarcq, Roderick T. Bunch, D Creswell et al. · PubMed · 1994 · 145 citations

Apoptosis, Cell Death, Cell Cycle +17

Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab

Kent Thudium, Mark Selby, Julie A. Zorn et al. · Cancer Immunology Research · 2022 · 75 citations · Full text

Ligands Mhc Ii, Immunology, Immunodominance +20